Heart Failure Pathophysiology

Heart failure is the clinical syndrome that results when the heart cannot pump or fill at a rate sufficient to meet the body's metabolic demands at normal filling pressures. Its pathophysiology is best understood as a progression: an initial injury or overload depresses pump function, compensatory neurohormonal and structural responses are recruited, and those same responses ultimately drive maladaptive remodelling and clinical deterioration.

Definition

Heart failure is a clinical syndrome in which structural or functional cardiac abnormality impairs ventricular filling or ejection, producing characteristic symptoms and signs together with neurohormonal activation and progressive cardiac remodelling.

Scope

This entry describes the mechanisms of the heart-failure syndrome — the haemodynamic derangement, the neurohormonal model, ventricular remodelling, and the distinction between failure with reduced and preserved ejection fraction. It is a reference and educational overview of pathophysiology and classification and does not provide individualised diagnostic or treatment recommendations.

Core questions

• How does an initiating injury or overload depress cardiac pump function?
• Why do compensatory neurohormonal responses become maladaptive over time?
• What distinguishes heart failure with reduced ejection fraction from that with preserved ejection fraction?
• How do metabolic and structural remodelling contribute to disease progression?

Key concepts

• Systolic versus diastolic dysfunction
• Reduced versus preserved ejection fraction
• Neurohormonal activation
• Ventricular remodelling
• Congestion and elevated filling pressures
• Myocardial energetic and metabolic dysfunction

Key theories

Neurohormonal hypothesis

Chronic activation of the sympathetic nervous system and the renin–angiotensin–aldosterone system, initially supporting perfusion, ultimately promotes vasoconstriction, sodium and water retention, fibrosis, and remodelling that worsen failure; this model reframed heart failure from a purely haemodynamic to a systemic disorder.

Ventricular remodelling

The progressive change in ventricular size, shape, and composition — hypertrophy, dilatation, fibrosis, and myocyte loss — through which the failing heart adapts maladaptively to sustained stress.

Mechanisms

An index event — myocardial infarction, pressure or volume overload, or a cardiomyopathic process — reduces the heart's ability to eject or fill. To preserve perfusion, the sympathetic nervous system and renin–angiotensin–aldosterone axis activate, raising heart rate, contractility, vascular tone, and salt and water retention. Over time these responses impose excess wall stress and neurohormonal toxicity, driving hypertrophy, chamber dilatation, interstitial fibrosis, and progressive myocyte loss — ventricular remodelling. Disturbed cardiac substrate metabolism and energetics further limit contractile reserve. The syndrome is described both as failure with reduced ejection fraction, dominated by impaired contraction and dilatation, and as failure with preserved ejection fraction, dominated by impaired relaxation and stiffening with congestion at near-normal ejection fraction.

Clinical relevance

This pathophysiology underlies the congestive symptoms and signs that define the syndrome and frames how cardiothoracic teams reason about candidates for revascularisation, valve surgery, mechanical support, or transplantation. The entry summarises mechanisms and classification for reference and is not a substitute for individualised clinical assessment or guideline-directed therapy.

Epidemiology

Heart failure is a common end stage of many cardiovascular diseases and a major cause of hospitalisation and mortality in ageing populations; contemporary society guidelines frame its diagnosis around ejection-fraction categories and the syndrome's high morbidity.

Evidence & guidelines

The neurohormonal and remodelling framework is consolidated in major reviews, and current diagnostic classification — including the reduced, mildly reduced, and preserved ejection-fraction categories — is set out in the 2021 ESC heart-failure guidelines.

History

Heart failure was long understood chiefly in haemodynamic terms, but the late twentieth century saw a decisive shift toward the neurohormonal model, which recognised that compensatory hormonal activation itself drives progression. This reframing, synthesised in Braunwald's accounts, reoriented both research and the conceptual basis of management.

Debates

Is heart failure with preserved ejection fraction a single entity?

Whether HFpEF represents one disease or a heterogeneous group of conditions sharing a clinical picture remains debated, complicating both classification and the mechanistic account of the syndrome.

Key figures

• Eugene Braunwald
• Joseph Hill
• Eric Olson
• Milton Packer

Seminal works

• braunwald-2015
• hill-olson-2008
• mcdonagh-2021

Frequently asked questions

What is the neurohormonal model of heart failure?

It holds that sustained activation of the sympathetic and renin–angiotensin–aldosterone systems, though initially compensatory, ultimately drives the fibrosis, remodelling, and progression that characterise the syndrome.

What is the difference between reduced and preserved ejection fraction heart failure?

Reduced ejection fraction failure reflects impaired contraction with a dilated, weakly ejecting ventricle, whereas preserved ejection fraction failure reflects a stiff, poorly relaxing ventricle that produces congestion despite a near-normal ejection fraction.